Table 2.
Subgroup analysis for smell dysfunction.
| Subgroup | Number of studies | Pooled prevalence % (95% CI) | I2 (%) | Test of difference within each subgroup | |
|---|---|---|---|---|---|
| Q | p | ||||
| Mean age | 3.35 | 0.067 | |||
| 0−10 | 3 | 6.34 (0.01–14.50) | 89.60 | ||
| >10 | 8 | 19.64 (7.98–31.31) | 88.30 | ||
| Percentage of male participants (%) | 5.08 | 0.024 | |||
| 0–50 | 2 | 51.14 (15.17–87.11) | 87.10 | ||
| >50 | 9 | 9.41 (4.68–14.14) | 99.00 | ||
| Area | 1.39 | 0.706 | |||
| Asia | 7 | 17.30 (6.51–28.09) | 96.80 | ||
| America | 2 | 17.80 (0.01-40.97) | 75.30 | ||
| Europe | 1 | 15.15 (2.92–27.38) | - | ||
| Africa | 1 | 10.87 (2.46–17.88) | - | ||
| Percentage of patients with mild or moderate COVID-19 (%) | 2.41 | 0.120 | |||
| 0–50 | 3 | 13.93 (4.47–23.38) | 44.40 | ||
| >50 | 1 | 5.41 (0.03–10.56) | - | ||
| Percentage of patients with comorbidities (%) | 0.81 | 0.369 | |||
| 0–10 | 2 | 2.67 (0.01–6.56) | 51.60 | ||
| >10 | 1 | 7.69 (0.01–17.93) | - | ||
| Quality score | 0.45 | 0.500 | |||
| 0–3 | 2 | 15.04 (6.62–23.45) | 43.40 | ||
| 4–6 | 10 | 21.09 (5.62–36.56) | 95.20 | ||